🇺🇸

IPO Capital Markets

· daily

US IPO Pipeline SEC S-1 Filings — April 06, 2026

The IPO Pipeline stream reveals five new or contextual S-1 filings on April 6, 2026, dominated by mixed/neutral sentiments with Legence Corp. as the standout positive amid acquisition-driven growth. Period-over-period trends show stark contrasts: TEN Holdings' core virtual events revenue declined 15.6% YoY to $2.7M (88.2% of total), while physical events grew 33.3% to $0.4M, contrasting Legence's pro forma revenue expansion to $3.45B for 2025 via Bowers acquisition (up from historical $2.55B). High dilution risks proliferate in 20/20 Biolabs (80% conversion discounts on $712K crowdfunding + $70K notes, warrants for 3.5M shares), SPAC regulatory hurdles in Mountain Crest (PRC VIE/CSRC risks), and resale dynamics in LB Pharma. Capital allocation leans toward growth retention (no dividends across filings), with Legence financing $426.6M M&A via $200M debt post-$780M IPO proceeds. Portfolio-level theme: Early-stage biotechs/events face dilution/revenue headwinds, while services M&A signals consolidation; watch S-1 effectiveness for IPO catalysts.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 03, 2026

The IPO Pipeline stream reveals a surge in activity with three new S-1 IPO filings (Auddia, VIDA Global, American Rebel) and two S-4 merger registrations (Prosperity Bancshares, Live Oak Acquisition Corp. V), highlighting a diverse mix of audio tech, AI, consumer holdings, banking, and SPAC de-SPAC plays amid a 2026 IPO resurgence. Overarching themes include pervasive execution risks like going concern opinions, Nasdaq compliance histories via reverse splits, founder voting controls exceeding 85%, and high redemption/dilution potentials, tempered by strategic M&A pursuits and committed financings such as $126.5M PIPE. Period trends show cash burn pressures (e.g., Auddia's $3.2M cash at Dec 31, 2025 despite $7.1M 2025 raise and $0.9M YTD to Mar 2026) contrasting with acquisition expansions (American Rebel's $20+MM in minority stakes). Mixed sentiments dominate (4/5 filings), with VIDA's positive outlook as the outlier in hot AI sector. Market implications point to volatile near-term pops for IPOs but elevated failure risks, regulatory bottlenecks as key catalysts, and opportunities in merger arb for fixed-ratio deals.

5 high priority 5 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 02, 2026

Three S-1 filings on April 2, 2026, signal a nascent IPO pipeline resurgence, featuring a blank-check SPAC (Churchill Capital Corp XII), a multi-geography operating company (TG-17, Inc.), and a consulting firm (Invech Holdings, Inc.), all with high materiality (9-10/10). Limited period-over-period data shows TG-17's balance sheets for Dec 31, 2024 vs 2025 with ongoing operations across US/Israel/France, but no YoY revenue/margin trends disclosed; subsequent events include stock issuances Jan-Mar 2026 indicating capital raises amid customer concentration risks. Churchill's sponsor commitment via 11.5M founder shares (post 2.875M surrender on Mar 16, 2026) and 350k private units highlights SPAC alignment, while Invech flags substantial going concern doubts with no adjustments. Neutral sentiment dominates (2/3 filings), but mixed for Invech underscores pre-IPO risks; no insider trading patterns, forward guidance, or capital returns noted across filings. Portfolio-level theme: High-risk IPO candidates with dilution potential from cheap founder shares/preferred stock, warranting watch for effectiveness and pricing catalysts amid neutral-to-mixed outlook.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 01, 2026

The IPO Pipeline stream features two key SEC filings: Expro Ltd's S-4 for redomiciliation to Cayman Islands with NYSE listing under XPRO, signaling structural optimization for growth, and TRIC Global's S-1 for an imminent IPO as a nascent Connect platform developer. Expro exhibits strong positive sentiment (9/10 materiality) with 10.5% holder Oak Hill Advisors committing to vote in favor, no operational changes, and minimal 1% dilution risk from withdrawals, positioning it for enhanced liquidity and flexibility. TRIC, incorporated December 2025, reports neutral sentiment (9/10 materiality) with zero revenue, expenses, compensation, facilities, patents, or governance structures for FY ended Dec 31, 2025, highlighting early-stage risks. No YoY/QoQ financial trends available across filings, but TRIC's $0 metrics vs Expro's established structure underscore a bifurcation in pipeline maturity. Portfolio-level theme: 1/2 filings show positive restructuring catalysts amid governance voids in new entrants, implying selective opportunities in relistings over pure IPOs. Market implications include near-term NYSE catalyst for Expro and prolonged scrutiny for TRIC's S-1 effectiveness.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 31, 2026

The March 31, 2026, IPO Pipeline stream reveals three S-1/S-4 filings dominated by pre-IPO preparations and merger activity, with neutral sentiment across all (Bitcoin Depot, VYNE Therapeutics, Churchill Capital Corp X). Overarching themes include aggressive share restructuring via reverse splits in 2/3 filings (Bitcoin Depot's 1-for-7 on Feb 23, 2026, reducing Class A shares 85.7% from 35.5M to 5.1M and Class M 85.7% from 37.8M to 5.4M; VYNE's potential post-merger split), signaling efforts to boost per-share metrics for listing compliance amid no disclosed financial trends. Churchill stands out as post-IPO SPAC (41.4M units sold May 15, 2025, full over-allotment exercised, no Founder Share forfeitures), targeting quantum tech via Infleqtion with Sponsor holding 10.35M cheap Founder Shares (initial $0.003/share). No period-over-period financials provided, but capital events like splits and low-cost equity issuance highlight capital allocation focus on dilution control. Market implications point to crypto/biotech/quantum sectors prepping for public markets, with reverse splits as potential distress flags but merger/SPAC paths offering de-SPAC catalysts. Portfolio-level pattern: 100% of filings involve restructuring (splits, conversions, capitalizations), prioritizing Nasdaq compliance over growth narratives.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 30, 2026

The IPO Pipeline stream features two SEC filings on March 30, 2026: Cadre Holdings' S-4 shelf registration for up to 7,500,000 shares to fund future acquisitions and Elmet Group Co.'s S-1 for its initial public offering on Nasdaq under 'ELMT'. No period-over-period financial comparisons are available, as Elmet's preliminary prospectus explicitly provides no financial performance data and Cadre's filing focuses on share registration without operational metrics. Neutral sentiment prevails across both, with Elmet carrying higher materiality (10/10) due to its IPO status as an emerging growth and smaller reporting company in fabricated metal products. Cadre signals proactive M&A strategy in safety equipment markets, while Elmet highlights speculative high-risk entry into public markets post-reorganization on January 2, 2026. Portfolio-level pattern: Early-stage capital market preparations amid neutral outlook, with no YoY/QoQ trends but potential for new listings and dilution. Market implications include monitoring for IPO catalysts and acquisition targets, positioning investors for alpha in industrials.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 27, 2026

The IPO pipeline shows a surge in biotech S-1 filings (Kailera, Alamar, FibroBiologics, VivoSim), highlighting clinical-stage companies with narrowing net losses (e.g., Kailera -32% YoY to $149M, Alamar reduced to $29.8M) but surging R&D expenses (Kailera +15x) and no revenues, amid mixed sentiments. Revenue standouts include Alamar's 195% YoY growth to $74.2M and 385% gross profit expansion, contrasting Yesway's flat inside sales (0.4% YoY) and -1.9% fuel volume decline in Q1 2026 prelims. M&A activity features Allegiant's mixed pro forma merger with Sun Country (revenue +44% to $3.7B but net loss widening slightly) and Avalanche's SPAC combo with $216M PIPE. SPAC IPO (Collective II) and post-IPO resales (WaterBridge) add neutral liquidity plays, while VivoSim and Fibro face acute risks (going concern, Nasdaq delisting). Portfolio trends reveal biotech loss compression averaging ~30% YoY but high dilution/execution risks; actionable now: monitor IPO pricing amid 2026 market volatility.

10 high priority 10 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 26, 2026

The IPO Pipeline stream shows heightened activity with two newly published SPAC-related filings (Maywood Acquisition Corp. 2 S-1 and Digital Asset Acquisition Corp. S-4) and one operating company IPO (CIMG Inc. S-1), all filed March 25-26, 2026, signaling a potential resurgence in SPAC and traditional IPO markets amid neutral sentiment across the board. Period-over-period data highlights SPAC IPO completions (e.g., Digital Asset's April 30, 2025 IPO) and CIMG's FY2025 financials with Q4 FY2025 trends, but lacks explicit YoY/QoQ growth numbers, focusing instead on structural setups like founder shares and concentrations. Key developments include Maywood's 10M unit IPO structure with 35% founder ownership post-offering, Digital Asset's de-SPAC with Old Glory (agreement Jan 13, 2026), and CIMG's acquisitions (e.g., Braincon Sep 23, 2025) amid customer/supplier concentrations. Portfolio-level patterns reveal standard SPAC dilution risks (founder shares at ~$0.01) and operating co risks from China/North America revenue splits, implying selective opportunities in monitoring IPO progressions. Market implications point to building catalyst calendars around S-1 effectiveness, business combinations, and warrant exercises, with high materiality (9-10/10) underscoring actionable intelligence for early positioning.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 25, 2026

The IPO Pipeline stream features two new S-1 filings published on March 25, 2026: Cryptex Digital Market Cap ETF providing exposure to top cryptocurrencies and Sensei Harbor Corp., a development-stage edtech firm with a recent app acquisition. No explicit period-over-period financial trends available due to both being pre-revenue or early-stage entities, but Sensei's accumulated deficit of $1,404 as of November 30, 2025, highlights nascent operations since founding in March 2025. Cryptex emphasizes historical shifts like Ethereum's 2022 Merge to proof-of-stake and Solana's disinflationary staking model decaying from 8% to 1.5% long-term. Overarching themes include high materiality (9-10/10), neutral-to-mixed sentiment, and substantial risks like crypto volatility for Cryptex and going concern doubts for Sensei. Market implications point to high-risk, high-reward pre-IPO opportunities in crypto and micro-cap tech amid regulatory uncertainties. Portfolio-level pattern: Both filings underscore investor appetite for speculative digital assets despite limited operational history.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 24, 2026

Four S-1 filings on March 24, 2026, underscore a diverse IPO pipeline: a new SPAC (Research Alliance Corp III), post-IPO amendment for Forgent Power Solutions (IPO closed Feb 6), proposed IPO for Arxis, and resale registration for biotech Artelo Biosciences amid distress signals. Overarching themes include standard SPAC protections, acquisition-driven asset buildup in power sector (FPS intangibles from PwrQ/States/VanTran/MGM), extensive regulatory/compliance risks (Arxis FCPA/ITAR/FAA), and dilution/Nasdaq pressures (Artelo 1-for-3 reverse split reducing shares 65% from 2.12M to 736K). No uniform period-over-period trends across filings, but FPS flags Q4 2025 customer concentration risk in revenue/accounts receivable, contrasting neutral sentiment in SPAC/FPS vs negative in Arxis and mixed in Artelo. Critical developments like FPS over-allotment options (Feb 9) and Artelo Nasdaq extension to March 30 imply near-term catalysts, with high materiality (9-10/10) signaling investor attention. Portfolio-level pattern: 75% neutral/mixed sentiment suggests resilient IPO momentum despite biotech distress, positioning SPACs/power plays for alpha amid aerospace/biotech hurdles.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 23, 2026

The IPO Pipeline stream shows robust activity with four filings on March 23, 2026, including three S-1s for share registrations/resales and one S-4 for a banking merger, signaling heightened pre-IPO and follow-on preparations amid a transitional market. AI Era Corp. (formerly AB International) generated $1.16M in new AI licensing revenue post-November 30, 2025, marking a pivot from streaming divestiture, while MobbQuest and AEVEX highlight microcap risks with going concern doubts and control weaknesses. Period-over-period, AI Era's revenue surged from zero historical base to $1.16M in ~4 months, contrasting MobbQuest's zero revenue and $11K deficit. The RMBI-Farmers merger offers consolidation value at $82.4M aggregate (~$44.71/share), positive amid sector M&A. Overarching themes include high-risk microcap IPO aspirants (3/4 filings) with low cash ($11.8K-$48K) and deficits ($10M+ in two cases), versus stable banking deal; implications point to volatile pipeline with merger as outlier stability.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 20, 2026

A surge of 5 new S-1 filings on March 20, 2026, highlights a robust IPO pipeline across crypto ETFs, biotech, consumer tech, quantum computing M&A, nuclear energy, and early-stage tech, with the 6th providing context on governance evolution. Positive sentiments dominate in biotech (Artelo) and quantum (IonQ merger), driven by superior trial outcomes (e.g., Artelo's 6.38% weight gain vs -5.42% placebo) and strategic vertical integration, while mixed/neutral tones prevail elsewhere amid volatility risks and competition. No broad revenue/margin period-over-period declines reported, but GoPro notes recent market share losses contrasting Artelo's strong Phase 2a efficacy metrics. Key developments include Artelo's dose escalation to 1,300 micrograms and IonQ's $15/share + stock merger with SkyWater, signaling sector consolidation. Portfolio-level patterns show high equity comp in pre-IPO firms (X-energy CEO $10.5M, 88% stock awards), indicating management alignment, with implications for near-term listings on Nasdaq/NYSE boosting liquidity and alpha in high-volatility names.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 19, 2026

Two S-1 IPO registration statements filed on March 19, 2026, highlight an active US IPO pipeline targeting autonomous robotics (Exyn Technologies) and nuclear energy (Eagle Nuclear Energy Corp.), reflecting investor interest in AI-driven autonomy and clean energy transitions amid 2026 market recovery. Exyn demonstrates superior operational metrics with positive sentiment (10/10 materiality), including 35% larger volume capture, 44% reduction in survey time (27 to 15 minutes), 97% faster setup (30 to under 1 minute), and 50% cost savings over 10 years in mining case studies, with thousands of autonomous flights since 2016 at Level 4B SAE autonomy. Eagle Nuclear shows neutral sentiment (9/10 materiality) with no revenue or earnings reported through 2025-12-31, but multiple capital raises via Regulation Crowdfunding (2025-04/05) and Private Placements (2024-2025), alongside uranium properties and heavy related-party involvement. No period-over-period financial trends available across filings, but Exyn's operational outperformance vs traditional methods signals strong pre-IPO momentum; Eagle's SPAC ties and offerings indicate funding access despite lacks. Portfolio-level theme: Early-stage IPOs prioritizing tech innovation over current profitability, with Exyn outperforming on metrics (e.g., 1cm accuracy, 2M data points/sec) relative to Eagle's neutral profile. Market implications include potential sector rotation into autonomy/mining/defense and nuclear revival, warranting watch for pricing catalysts.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 18, 2026

The single S-4 filing in the IPO Pipeline stream highlights a high-materiality (9/10) SPAC merger to form Pubco, a digital asset treasury company with primary XRP exposure, backed by over $1B in equity commitments at $10.00 per share and initial holdings of at least 473M XRP from Ripple and sponsors. Mixed sentiment stems from strong structural support like Up-C tax efficiency, six-month lockups on key shares, and a fairness opinion from CCM, offset by risks such as high SPAC redemptions potentially dropping cash below the $5M closing minimum and minority positioning for existing SPAC shareholders. No period-over-period financial trends are disclosed in the filing, but the transaction implies robust pre-merger capital inflows versus typical SPAC dilutions. Leadership by CEO Asheesh Birla and Ripple advisors signals conviction in XRP yield generation and ecosystem strategies. This positions Pubco as a rare public vehicle for concentrated XRP exposure amid crypto market volatility, with implications for IPO-like liquidity in digital assets. Portfolio-level theme: Resurgent SPAC activity targeting niche crypto treasuries despite redemption pressures.

1 high priority 1 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 17, 2026

The IPO Pipeline stream on March 17, 2026, captures two high-materiality filings: Rallybio Corp's S-4 for its merger with Candid Therapeutics (mixed sentiment) and AmperCap Acquisition Company's S-1 for a $125M SPAC IPO (neutral sentiment). Both entities exhibit no revenues to date, reflecting pre-operational stages with zero YoY/QoQ revenue growth and flat operational metrics, underscoring high-risk development plays. Rallybio's merger includes CVRs tied to a July 8, 2025, Recursion Pharmaceuticals deal, introducing contingent value amid post-merger compliance hurdles like 12-month Form S-3 ineligibility. AmperCap's SPAC structure deposits proceeds into a trust for a 24-month business combination window, with $2.5M underwriting discounts and $4M working capital needs. Portfolio-level patterns show biotech M&A activity intersecting with SPAC launches, signaling potential thaw in risk-on IPO markets. Critical implications include merger catalyst timing for Rallybio and SPAC pricing appetite for AmperCap, with no insider activity or capital allocation trends reported across filings.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 16, 2026

The IPO Pipeline stream saw limited but material activity on March 16, 2026, with two filings: MasterCraft Boat Holdings' S-4 registering shares for its February 5, 2026 merger with Marine Products, and Presidio Production Co's S-1 advancing its post-SPAC IPO in crude oil/gas production. MasterCraft's pro forma financials reveal combined net sales of $509M for YE June 30, 2025 (up from implied historical segments) but sharp income decline to $10M from historical ~$25M sum (~60% drop due to $65M goodwill, $62M intangibles amortization, and expenses), signaling earnings dilution post-merger. Presidio's filing incorporates recent March 4, 2026 credit agreement and December 31, 2025 reserve reports, with no metrics provided but neutral sentiment amid governance updates post-August 2025 SPAC merger. Cross-filing trends show pro forma balance sheet strength (MasterCraft assets $436M, equity $343M) contrasting absent financials in Presidio, highlighting marine sector consolidation versus energy de-SPAC momentum. Market implications include potential boating market share gains for MasterCraft amid cyclical recovery, while Presidio adds to oil/gas public supply; overall quiet session underscores selective IPO/M&A pipelines in niche sectors.

2 high priority 2 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 13, 2026

The IPO pipeline shows robust activity with 6 S-1 filings on March 13, 2026, dominated by SPACs (2/6), bank mutual-to-stock conversions (2/6), a microcap tech play, and a crypto ETF, highlighting diverse entry points into public markets amid limited traditional IPOs. No broad period-over-period financial trends available due to pre-IPO status, but common $10/share pricing in 4/6 filings signals standardized valuation approach for SPACs and banks versus Dravica's $0.03 outlier. Positive sentiment in CSB Financial contrasts with Dravica's negative going concern flag and JATT II's dilution risks, while neutrals dominate. Bank conversions emphasize depositor/plan priorities for subscription success, SPACs offer dry powder with 24-month windows, and niche plays like crypto staking add volatility. Portfolio implications favor monitoring bank conversions for stable liquidity events and SPACs for M&A catalysts, with cross-filing comparison revealing CSB's $14.55M proceeds potential outperforming Dravica's $120k micro-raise.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 12, 2026

The IPO Pipeline stream shows limited but notable activity with two newly published filings: TIAA Real Estate Account's S-1 Pre-Effective Amendment No. 1 for a continuous Rule 415 offering of tax-deferred variable annuity interests focused on direct real estate (75-85% allocation), signaling ongoing capital access amid real estate volatility risks. Digimarc's S-4 proxy/prospectus outlines a reorganization into Deschutes Parent, Inc., followed by LLC conversion with 1:1 share exchanges, alongside director elections and auditor ratification, with a recent FY2025 10-K providing context. Devon Energy's S-4 (contextual) details a tax-free merger acquiring Coterra Energy, expected to close Q2 2026, creating a larger entity but with mixed sentiment due to closing risks and no appraisal rights. No period-over-period financial trends (YoY/QoQ revenue, margins) or operational metrics are disclosed across filings, highlighting a focus on structural changes rather than performance data. Overarching themes include tax-efficient reorganizations (IRC Sections 368(a)(1)(F) and 368(a)), low REIT exposure (TIAA at 0% as of Dec 31, 2025), and energy consolidation, with neutral sentiment dominating (2/3 filings). Market implications point to potential new investment vehicles in real estate annuities, corporate flexibility plays, and M&A-driven scale in energy, warranting monitoring of catalysts like shareholder votes and regulatory clearances for IPO/follow-on impacts.

3 high priority 3 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 11, 2026

The IPO pipeline shows robust activity with 4 S-1 filings on March 11, 2026, including a new SPAC targeting consumer goods (BEST SPAC II), mining prep (Bunker Hill), a $200M debt follow-on (OFG Bancorp), and a high-risk dev-stage eCommerce play (OXO), with first 2 newly published signaling fresh momentum. Period data reveals stark contrasts: OXO's inception-period net loss of $4,701 and cash at $400 highlight early-stage vulnerabilities, while Bunker Hill's asset acquisitions (e.g., Pend Oreille Mill Aug 2024) and serial financings indicate operational ramp-up absent YoY metrics. BEST SPAC II's cheap founder shares ($0.0079/share) and sponsor commitment reflect strong skin-in-the-game, contrasting OXO's going concern doubts. Neutral/mixed sentiments dominate (3/4), but positive SPAC vibe suggests deSPAC catalysts ahead; portfolio trend of debt-heavy structures (Bunker loans, OFG notes, SPAC redemptions up to 15%) flags leverage risks amid no revenue growth visibility across filings. Market implications: Watch SPAC IPO execution for consumer sector entry, but avoid dev-stage traps without traction.

4 high priority 4 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 10, 2026

The IPO Pipeline stream features a single high-materiality S-1 filing from Pershing Square Capital Management (PSCM) on March 10, 2026, signaling an imminent IPO via its flagship NYSE-listed vehicle PSUS, focused on minority stakes in high-quality growth companies. Key developments include the completed Howard Hughes Transaction on May 5, 2025, which transformed HHH into a diversified holding company, and the $2.1B Vantage Acquisition announced December 17, 2025, slated for Q2 2026 close, enhancing portfolio scale amid a $3.75M quarterly HHH Base Management Fee structure. Positive sentiment dominates with emphasis on long-term value creation and synergies, though risks like concentrated exposure are noted; no explicit period-over-period financial trends are detailed in the filing referencing Q/E September 30, 2025. This filing underscores a bullish resurgence in investment management IPOs, positioning PSCM as a portfolio-level outlier in concentrated activist strategies. Market implications include potential pre-IPO hype and post-listing catalysts from deal integrations, with no cross-filing comparisons available due to single entry.

1 high priority 1 total filings